Daiichi Sankyo and AstraZeneca have received approval from China's National Medicinal Products Administration (NMPA) for Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer who have previously received trastuzumab-based therapy[1]. It is a monotherapy intended for the second line of treatment, which represents a shift from the previous indication in the third line and fills an important clinical gap[1]. The approval was granted on January 22, 2026, based on data from the phase III clinical trial DESTINY-Gastric04[1]. Enhertu is a specifically designed HER2-targeted antibody and cytostatic (ADC) drug[1]. This second-line indication expands the potential market by approximately 30% compared to the previous third-line only indication[1]. The drug is eligible for negotiations to be included in China's National Reimbursed Drug List (NRDL) in category 1 in 2026 and already has priority review status[1]. Enhertu continues to expand its position in the treatment of HER2-positive tumors, already having approvals for the treatment of breast and gastric cancer at the global level[1].